Assessment of disability and disease burden in neuromyelitis optica spectrum disorders in the CIRCLES Cohort
- PMID: 39477975
- PMCID: PMC11525583
- DOI: 10.1038/s41598-024-75013-z
Assessment of disability and disease burden in neuromyelitis optica spectrum disorders in the CIRCLES Cohort
Abstract
Neuromyelitis optica spectrum disorders (NMOSD) comprise autoimmune diseases imposing substantial disability. We compared an NMOSD-targeted disability assessment of mobility, vision, and self-care domains (individually and composite) with the multiple sclerosis-targeted Expanded Disability Status Scale (EDSS) to assess NMOSD disease burden. An overall cohort (n = 505) and a subset of these patients with an enriched dataset (n = 198) were analyzed from the CIRCLES longitudinal, observational database of patients with AQP4-IgG-seropositive or -seronegative NMOSD in North America. Multinomial modeling was used to identify temporal correlates of disability improvement, stability, and worsening. Prior on-study relapse correlated with worsening mobility (OR, 3.08; 95% CI: 1.61-5.90), vision (OR, 3.99; 95% CI: 2.03-7.86), self-care disability (OR, 1.90; 95% CI: 1.07-3.38), and mean composite index disability (OR, 4.20; 95% CI: 1.71-10.34). Higher vision disability was associated with Black race, shorter time on-study, and AQP4-IgG-seropositive status in patients ≥ 18 years (p < 0.05). Disease onset phenotype and sex correlated with pain interference (p < 0.05). These correlates of NMOSD disability were undetected by EDSS. The CIRCLES real-world experience supports the need for NMOSD-specific disability assessment to improve recognition of disease burden, facilitate proactive clinical management, offer insights into resilience, and inform clinical trial design.
© 2024. The Author(s).
Conflict of interest statement
The CIRCLES study was sponsored by The Guthy-Jackson Charitable Foundation. The present study was funded by Genentech, Inc. S. Gholizadeh is an employee of Genentech, Inc., and shareholder of F. Hoffmann-La Roche Ltd. A. Exuzides was an employee of Genentech, Inc., at the time of this study and manuscript preparation and is a shareholder of F. Hoffmann-La Roche Ltd. J. Sinnott has received research support from the Guthy-Jackson Charitable Foundation and the National Institutes of Health (NIH). C. Palmer and M. Waltz declare they have nothing to disclose. J. Rose has received research support from the National Multiple Sclerosis Society, Guthy-Jackson Charitable Foundation, NIH, Friends of MS, Biogen, and the US Department of Veterans Affairs. He has received intellectual property interests from a discovery or technology relating to health care. A. Jolley and J.M. Behne declare they have nothing to disclose. M.K. Behne has received personal compensation for serving as an independent contractor with the Guthy-Jackson Charitable Foundation. T.F. Blaschke has received personal compensation for serving as a consultant for Merck, the Guthy-Jackson Charitable Foundation, and the Bill and Melinda Gates Foundation. He has received personal compensation for serving as an officer or member of the board of directors for Durect. He has received personal compensation for serving as an editor, associate editor, or editorial advisory board member for Annual Reviews. He has received stock or ownership interest from Durect. He has received research support from the Bill and Melinda Gates Foundation. T.J. Smith has received personal compensation for serving as a consultant for Horizon and Immunovant. He has received personal compensation for serving on a scientific advisory or data safety monitoring board for Horizon. He has received intellectual property interests from a discovery or technology relating to health care. He is an advisor to the Guthy-Jackson Charitable Foundation. M.R. Yeaman has received personal compensation for serving on a scientific advisory committee for Genentech, Alexion, and Horizon. He has received research support from the NIH and US Department of Defense. He has received intellectual property interests from a discovery or technology relating to health care. He is an advisor to the Guthy-Jackson Charitable Foundation. K. Lewis declares she has nothing to disclose. L. Cook has received research support from the Centers for Disease Control and Prevention, Guthy-Jackson Charitable Foundation, Utah Highway Safety Office, and NIH.
Figures
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
